[1]马丽丽,付长江.存活素和细胞周期素依赖性蛋白激酶抑制因子2B在骨髓增生异常综合征诊断及患者预后评估中的临床价值研究[J].陕西医学杂志,2024,(3):348-351,356.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.013]
　MA Lili,FU Changjiang.Clinical value of Survivin and P15INK4B in diagnosis of myelodysplastic syndrome and prognosis evaluation of patients[J].,2024,(3):348-351,356.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.013]
点击复制

存活素和细胞周期素依赖性蛋白激酶抑制因子2B在骨髓增生异常综合征诊断及患者预后评估中的临床价值研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年3期
页码:
348-351,356
栏目:
临床研究
出版日期:
2024-03-05

文章信息/Info

Title:
Clinical value of Survivin and P15INK4B in diagnosis of myelodysplastic syndrome and prognosis evaluation of patients
作者:
马丽丽1; 付长江2
(1.赤峰市医院血液科,内蒙古 赤峰 024000; 2.赤峰学院附属医院介入科,内蒙古 赤峰 024000)
Author(s):
MA Lili; FU Changjiang
(Department of Hematology,Chifeng Municipal Hospital,Chifeng 024000,China)
关键词:
骨髓增生异常综合征;  存活素;  细胞周期素依赖性蛋白激酶抑制因子2B;  预后;  联合检测
Keywords:
Myelodysplastic syndrome;  Survivin;  P15INK4B;  Prognosis;  Combined detection
分类号:
R 551.3
DOI:
DOI:10.3969/j.issn.1000-7377.2024.03.013
文献标志码:
A
摘要:
目的:探讨存活素(Survivin)和细胞周期素依赖性蛋白激酶抑制因子2B(P15INK4B)在骨髓增生异常综合征(MDS)诊断及患者预后评估中的临床价值。方法:选取MDS患者150例为观察组,另选取同期体检健康者150例为对照组,比较Survivin、P15INK4B阳性表达及mRNA相对表达水平。对观察组患者进行为期1年的预后随访,比较不同预后患者Survivin、P15INK4B mRNA相对表达水平。绘制受试者工作特征曲线(ROC)曲线分析Survivin、P15INK4B对MDS的诊断价值,以及对MDS患者不良预后的评估价值。结果:观察组Survivin阳性表达率及mRNA表达水平高于对照组,P15INK4B阳性表达率及mRNA表达水平低于对照组(均P<0.05)。150例MDS患者中50例病死,1年生存率为66.67%(100/150),病死组Survivin mRNA表达水平高于存活组,P15INK4B mRNA表达水平低于存活组(均P<0.05)。Survivin、P15INK4B对MDS均有较高诊断价值,两者联合检测的诊断价值更高(均P<0.05)。Survivin、P15INK4B对MDS患者不良预后均有较高评估价值,两者联合检测的评估价值更高(均P<0.05)。结论:MDS患者Survivin高表达,且与患者预后呈正相关; P15INK4B低表达,且与患者预后呈负相关; 两者均可用于MDS的诊断及不良预后的评估,联合检测有更高的价值。
Abstract:
Objective:To investigate the clinical value of Survivin and cyclin dependent kinase inhibitor 2B(P15INK4B)in diagnosis of myelodysplastic syndrome(MDS)and prognosis evaluation of patients.Methods:A total of 150 MDS patients were selected as the observation group,and 150 healthy people in the same period were selected as the control group.The positive expression and mRNA relative expression levels of Survivin and P15INK4B were compared.The patients in the observation group were followed up for 1 year,and the relative expression levels of Survivin and P15INK4B mRNA in patients with different prognosis were compared.ROC curve was drawn to analyze the diagnostic value of Survivin and P15INK4B in MDS and the evaluation value of poor prognosis of MDS patients.Results:The positive expression rate and mRNA expression level of Survivin in the observation group were higher than those in the control group,and the positive expression rate and mRNA expression level of P15INK4B in the observation group were lower than those in the control group(all P<0.05).Among 150 MDS patients,50 patients died,and the 1-year survival rate was 66.67%(100/150).The expression level of Survivin mRNA in the death group was higher than that in the survival group,and the expression level of P15INK4B mRNA was lower than that in the survival group(all P<0.05).Both Survivin and P15INK4B had high diagnostic value for MDS,and the combined detection of Survivin and p15INK4B had a higher diagnostic value(all P<0.05).Survivin and P15INK4B had a high evaluation value for the poor prognosis of MDS patients,and the combined detection of Survivin and p15INK4B had a higher evaluation value(all P<0.05).Conclusion:The expression of Survivin is high in MDS patients and positively correlated with the prognosis of the patients.The expression of P15INK4B was low and negatively correlated with the prognosis of patients.Both of them can be used for the diagnosis of MDS and the evaluation of poor prognosis,and combined detection has higher value.

参考文献/References:

[1] 李荣芳,金龙,赵立丹.外周血T细胞免疫球蛋白黏蛋白-3和血清乳酸脱氢酶联合检测在骨髓增生异常综合征诊断中的应用价值[J].陕西医学杂志,2021,50(9):1143-1146.
[2] 李振波,陆诚.阿扎胞苷治疗骨髓增生异常综合征合并额外性梳样蛋白1基因突变疗效及安全性分析[J].陕西医学杂志,2021,50(9):1135-1138,1142.
[3] 张文荟,陈香丽,裴晓杭,等.骨髓增生异常综合征-难治性贫血伴原始细胞增多患者应用重组人血小板生成素对地西他滨联合预激方案治疗效果的影响[J].中华实用诊断与治疗杂志,2020,34(1):81-84.
[4] 朱晓华,王建成,程彦,等.外周血涂片骨髓细胞形态及骨髓活检联合检测对骨髓增生异常综合征的诊断价值[J].河北医学,2021,27(6):906-910.
[5] BOUCHLA A,THOMOPOULOS T P,PAPAGEORGIOU S G,et al.Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine[J].Epigenomics,2021,13(14):1129-1143.
[6] 王方方,杭筱,施青青,等.Tim3在再生障碍性贫血和骨髓增生异常综合征鉴别诊断中的意义[J].南京医科大学学报:自然科学版,2020,40(3):403-408.
[7] OWENS T J,PATEL S A,GREINER T C,et al.High-grade myelodysplastic syndrome in a pediatric multi-organ transplant recipient:A case report and literature review[J].Pediatr Transplant,2022,26(5):14287.
[8] 贾睿之.地西他滨联合支持治疗对骨髓增生异常综合征疗效及不良反应影响[J].中国药物与临床,2020,20(8):1373-1375.
[9] 曹亮,谢军,曾海燕,等.亮氨酸重复序列和免疫球蛋白样结构域1、存活蛋白在胶质瘤中的表达及对患者远期预后的影响[J].癌症进展,2022,20(16):1726-1728.
[10] 中华医学会血液学分会.骨髓增生异常综合征中国诊断与治疗指南(2019年版)[J].中华血液学杂志,2019,40(2):89-97.
[11] 刘欣,刘艳芬,孙旭,等.血速升颗粒联合复方黄黛片治疗骨髓增生异常综合征化疗相关血细胞减少临床研究[J].陕西中医,2021,42(1):78-80.
[12] 尹婉宜,沈扬,张丽红,等.青黄散加解毒化瘀方治疗骨髓增生异常综合征疗效及对患者血清可溶性细胞间黏附分子-1、转化生长因子-β1的影响[J].陕西中医,2022,43(8):1056-1059.
[13] 叶成林,姚永华,陈真,等.骨髓活检塑胶包埋在以单纯血小板减少为表现的骨髓增生异常综合征诊断中的应用价值[J].诊断学理论与实践,2020,19(2):177-181.
[14] 岳虹,张静妮.血清LDH、CA153、FA和Hcy水平检测在MA和MDS临床鉴别诊断中的作用研究[J].检验医学与临床,2020,17(19):2862-2865.
[15] 张永晓,李英华.miR-17-5p通过靶向SETD2调控骨髓增生异常综合征SKM-1细胞的增殖与凋亡[J].中国肿瘤生物治疗杂志,2022,29(1):30-36.
[16] GONDEK L P,DEZERN A E.Assessing clonal haematopoiesis:Clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states[J].Lancet Haematol,2020,7(1):73-81.
[17] CHEN Y,ZHONG Y,YE J X,et al.Facile label-free electrochemical DNA biosensor for detection of osteosarcoma-related survivin gene[J].Biosensors(Basel),2022,12(9):747.
[18] NING H M,WANG J,SU Y F,et al.Newly diagnosed acute myeloid leukemia patients-derived bone marrow mesenchymal stem cells suppress daunorubicin induced HL-60 cell apoptosis via modulating Caspase-3/Survivin[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi,2019,27(6):1736-1741.
[19] 胡绍波,李珊,邹毅,等.血浆细胞周期素依赖性蛋白激酶抑制因子、环腺苷酸反应元件结合蛋白水平与糖尿病视网膜病变关系研究[J].安徽医药,2022,26(1):168-172.
[20] XIA Y,LIU Y,YANG C,et al.Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis[J].Nat Commun,2021,12(1):2047.
[21] MINAIYAN G,SHAFIEE F,AKBARI V.Survivin promoter-driven DFF40 gene expression sensitizes melanoma cancer cells to chemotherapy[J].Int J Toxicol,2021,40(4):380-387.
[22] LOUNTOS G T,CHERRY S,TROPEA J E,et al.Structural basis for cell type specific DNA binding of C/EBPβ:The case of cell cycle inhibitor p15INK4b promoter[J].J Struct Biol,2022,214(4):107918.
[23] EBRAHIMIYAN H,GHARIBDOOST F,ASLANI S,et al.MicroRNAs are potentially regulating the survivin gene in PBMCs from systemic sclerosis patients[J].Mod Rheumatol,2020,30(5):862-869.
[24] LIN T Y,CHAN H H,CHEN S H,et al.BIRC5/Survivin is a novel ATG12-ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells[J].Autophagy,2020,16(7):1296-1313.
[25] 虞亚菲,王驰,常青,等.骨髓增生异常综合征GSTM5基因启动子区甲基化的状态及意义[J].中华检验医学杂志,2022,45(5):494-501.
[26] FAROOQ U,SARAVANAN B,ISLAM Z,et al.An interdependent network of functional enhancers regulates transcription and EZH2 loading at the INK4a/ARF locus[J].Cell Rep,2021,34(12):108898.

相似文献/References:

[1]聂泽强,李晓云,马爻芳,等.WT1基因在骨髓增生异常综合征患者外同血中的表达及临床意义[J].陕西医学杂志,2019,(8):977.
　NIE Zeqiang,LI Xiaoyun,MA Yaofang,et al.Expression of WT1 gene in patients with Myelodysplastic syndrome[J].,2019,(3):977.
[2]董 曼,王月莉.不同剂量地西他滨对骨髓增生异常综合征小鼠Beclin1蛋白表达的影响[J].陕西医学杂志,2021,50(6):657.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.004]
　DONG Man,WANG Yueli.Effects of different doses of decitabine on Beclin1 protein expression in mice with myelodysplastic syndrome[J].,2021,50(3):657.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.004]
[3]李振波,陆 诚.阿扎胞苷治疗骨髓增生异常综合征合并额外性梳样蛋白1基因突变疗效及安全性分析[J].陕西医学杂志,2021,50(9):1135.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.023]
　LI Zhenbo,LU Cheng.Efficacy and safety of azacitidine in treatment of MDS with ASXL1 gene mutation[J].,2021,50(3):1135.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.023]
[4]李荣芳,金 龙,赵立丹.外周血T细胞免疫球蛋白黏蛋白-3和血清乳酸脱氢酶联合检测在骨髓增生异常综合征诊断中的应用价值[J].陕西医学杂志,2021,50(9):1143.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.025]
　LI Rongfang,JIN Long,ZHAO Lidan.Application value of combined detection of peripheral blood TIM-3 and serum LDH in diagnosis of MDS[J].,2021,50(3):1143.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.025]
[5]王美佳,刘虹伶,曾依伶.地西他滨联合HA方案治疗骨髓增生异常综合征疗效及安全性研究[J].陕西医学杂志,2023,52(12):1731.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.023]
　WANG Meijia,LIU Hongling,ZENG Yiling.Efficacy and safety of decitabine combined with harringtonine and cytarabine regimen in treatment of myelodysplastic syndrome[J].,2023,52(3):1731.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.023]

备注/Memo

备注/Memo:
基金项目:内蒙古自治区卫生健康委员会医疗卫生科技计划项目(2020MS06524)
更新日期/Last Update: 2024-03-05